Low-dose cyclosporin therapy for recombinant erythropoietin-induced pure red-cell aplasia.
Duffield
Jeremy S
JS
Department of Renal Medicine, Royal Infirmary, Lauriston Place, Edinburgh, UK. j.duffield@ed.ac.uk
Mann
Susan
S
Horn
Lichel
L
Winney
Robin J
RJ
D016572:Cyclosporine / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004921:Erythropoietin / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007676:Kidney Failure, Chronic / Q000175:diagnosis / Q000628:therapy; D008875:Middle Aged; D011994:Recombinant Proteins; D012010:Red-Cell Aplasia, Pure / Q000139:chemically induced* / Q000188:drug therapy*; D018570:Risk Assessment; D016896:Treatment Outcome
D011994:Recombinant Proteins; D004921:Erythropoietin; D016572:Cyclosporine